Literature DB >> 8269393

Epidemiologic evidence for multiple sclerosis as an infection.

J F Kurtzke1.   

Abstract

The worldwide distribution of multiple sclerosis (MS) can be described within three zones of frequency: high, medium, and low. The disease has a predilection for white races and for women. Migration studies show that changing residence changes MS risk. Studies of persons moving from high- to low-risk areas indicate that in the high-risk areas, MS is acquired by about age 15. Moves from low- to high-risk areas suggest that susceptibility is limited to persons between about ages 11 and 45. MS on the Faroe Islands has occurred as four successive epidemics beginning in 1943. The disease appears to have been introduced by British troops who occupied the islands for 5 years from 1940, and it has remained geographically localized within the Faroes for half a century. What was introduced must have been an infection, called the primary MS affection (PMSA), that was spread to and from successive cohorts of Faroese. In this concept, PMSA is a single widespread systemic infectious disease (perhaps asymptomatic) that only seldom leads to clinical neurologic MS. PMSA is also characterized by a need for prolonged exposure, limited age of susceptibility, and prolonged incubation. I believe that clinical MS is the rare late outcome of a specific, but unknown, infectious disease of adolescence and young adulthood and that this infection could well be caused by a thus-far-unidentified (retro)virus.

Entities:  

Mesh:

Year:  1993        PMID: 8269393      PMCID: PMC358295          DOI: 10.1128/CMR.6.4.382

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  205 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  Studies on multiple sclerosis in Winnepeg, Manitoba, and New Orleans, Louisiana. I. Prevalence; comparison between the patient groups in Winnipeg and New Orleans.

Authors:  K B WESTLUND; L T KURLAND
Journal:  Am J Hyg       Date:  1953-05

3.  Immunogenetic profile of multiple sclerosis in Mexicans.

Authors:  C Gorodezky; R Najera; B E Rangel; L E Castro; J Flores; G Velázquez; J Granados; J Sotelo
Journal:  Hum Immunol       Date:  1986-08       Impact factor: 2.850

4.  A case-control study of multiple sclerosis.

Authors:  E A Operskalski; B R Visscher; R M Malmgren; R Detels
Journal:  Neurology       Date:  1989-06       Impact factor: 9.910

5.  The incidence and prevalence of multiple sclerosis in Newfoundland and Labrador, 1960-1984.

Authors:  W E Pryse-Phillips
Journal:  Ann Neurol       Date:  1986-09       Impact factor: 10.422

6.  Epidemiology of multiple sclerosis in western Poland--a comparison between prevalence rates in 1965 and 1981.

Authors:  M Wender; D Pruchnik-Grabowska; H Hertmanowska; P Kowal; M Zielińska; I Namysł; J Marcinkowski
Journal:  Acta Neurol Scand       Date:  1985-08       Impact factor: 3.209

7.  Prevalence of multiple sclerosis in north-east Scotland.

Authors:  D I Shepherd; A W Downie
Journal:  Br Med J       Date:  1978-07-29

8.  Prevalence of multiple sclerosis in Saskatoon.

Authors:  W J Hader
Journal:  Can Med Assoc J       Date:  1982-08-15       Impact factor: 8.262

9.  Multiple sclerosis in New Orleans, Louisiana, and Winnipeg, Manitoba, Canada: follow-up of a previous survey in New Orleans, and comparison between the patient populations in the two communities.

Authors:  A Stazio; R M Paddison; L T Kurland
Journal:  J Chronic Dis       Date:  1967-05

10.  Multiple sclerosis in a migrant population: 2. Half-orientals immigrating in childhood.

Authors:  J F Kurtzke
Journal:  Ann Neurol       Date:  1980-09       Impact factor: 10.422

View more
  121 in total

1.  Age dependence of clinical and pathological manifestations of autoimmune demyelination. Implications for multiple sclerosis.

Authors:  M E Smith; N L Eller; H F McFarland; M K Racke; C S Raine
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

Review 2.  The genetic epidemiology of multiple sclerosis.

Authors:  A Compston
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

Review 3.  Pleuropulmonary manifestations of systemic lupus erythematosus.

Authors:  M P Keane; J P Lynch
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

4.  Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis.

Authors:  Laurence M Howard; Serge Ostrovidov; Cassandra E Smith; Mauro C Dal Canto; Stephen D Miller
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 5.  Regulation of experimental autoimmune encephalomyelitis by chemokines and chemokine receptors.

Authors:  Adam Elhofy; Kevin J Kennedy; Brian T Fife; William J Karpus
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

6.  CD28 costimulatory blockade exacerbates disease severity and accelerates epitope spreading in a virus-induced autoimmune disease.

Authors:  K L Neville; M C Dal Canto; J A Bluestone; S D Miller
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 7.  Management of secondary-progressive multiple sclerosis.

Authors:  Gavin Giovannoni
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 8.  Axonal pathology and demyelination in viral models of multiple sclerosis.

Authors:  Jane E Libbey; Thomas E Lane; Robert S Fujinami
Journal:  Discov Med       Date:  2014 Jul-Aug       Impact factor: 2.970

9.  Uncoupling protein 2 has protective function during experimental autoimmune encephalomyelitis.

Authors:  Susanne Vogler; Jens Pahnke; Sophie Rousset; Daniel Ricquier; Holger Moch; Bruno Miroux; Saleh M Ibrahim
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

Review 10.  The role of infections in autoimmune disease.

Authors:  A M Ercolini; S D Miller
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.